Foghorn Therapeutics Raises ~$110 Million Through Direct Offering
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Express News | Foghorn Therapeutics Inc.: Extends Cash Runway Into 2027
Express News | Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Foghorn Prices $110M Mixed-shelf Registered Direct Offering
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. ("Foghorn") (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common
Investors Don't See Light At End Of Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Tunnel And Push Stock Down 25%
Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares have had a horrible month, losing 25% after a relatively good period beforehand. Instead of being rewarded, shareholders who have already held through
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, a
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, and expected value was -0.63 dollars.
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
Foghorn Therapeutics | 10-Q: Quarterly report
Press Release: Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Foghorn(R) Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2024.
Foghorn Therapeutics Cash, Cash Equivalents, and Marketable Securities of $206.7 M, as of March 31 >FHTX
Foghorn Therapeutics Cash, Cash Equivalents, and Marketable Securities of $206.7 M, as of March 31 >FHTX
Foghorn Therapeutics 1Q Loss/Shr 59c >FHTX
Foghorn Therapeutics 1Q Loss/Shr 59c >FHTX
Foghorn Therapeutics 1Q Loss $25M >FHTX
Foghorn Therapeutics 1Q Loss $25M >FHTX
Analysts' Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53
Even though Foghorn Therapeutics Inc. (NASDAQ:FHTX) has fallen by 31% over the past week , insiders who sold US$72k worth of stock over the past year have had less luck.
Press Release: Foghorn Therapeutics Strengthens Financial Leadership With Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn(R) Therapeutics Inc. (
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush